- Home
- AMTM vs SEPN Comparison
AMTM vs SEPN Comparison
Compare AMTM & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTM
- SEPN
- Stock Information
- Founded
- AMTM 2020
- SEPN 2022
- Country
- AMTM United States
- SEPN United States
- Employees
- AMTM N/A
- SEPN N/A
- Industry
- AMTM
- SEPN
- Sector
- AMTM
- SEPN
- Exchange
- AMTM NYSE
- SEPN NYSE
- Market Cap
- AMTM 5.6B
- SEPN 453.2M
- IPO Year
- AMTM N/A
- SEPN 2024
- Fundamental
- Price
- AMTM $24.29
- SEPN $11.40
- Analyst Decision
- AMTM Buy
- SEPN Strong Buy
- Analyst Count
- AMTM 6
- SEPN 5
- Target Price
- AMTM $25.50
- SEPN $26.75
- AVG Volume (30 Days)
- AMTM 2.3M
- SEPN 539.1K
- Earning Date
- AMTM 08-05-2025
- SEPN 08-15-2025
- Dividend Yield
- AMTM N/A
- SEPN N/A
- EPS Growth
- AMTM N/A
- SEPN N/A
- EPS
- AMTM 0.10
- SEPN N/A
- Revenue
- AMTM $11,261,000,000.00
- SEPN $977,000.00
- Revenue This Year
- AMTM $70.67
- SEPN N/A
- Revenue Next Year
- AMTM $2.35
- SEPN $526.96
- P/E Ratio
- AMTM $254.39
- SEPN N/A
- Revenue Growth
- AMTM 38.56
- SEPN 108.76
- 52 Week Low
- AMTM $16.01
- SEPN $4.17
- 52 Week High
- AMTM $34.50
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- AMTM N/A
- SEPN N/A
- Support Level
- AMTM N/A
- SEPN N/A
- Resistance Level
- AMTM N/A
- SEPN N/A
- Average True Range (ATR)
- AMTM 0.00
- SEPN 0.00
- MACD
- AMTM 0.00
- SEPN 0.00
- Stochastic Oscillator
- AMTM 0.00
- SEPN 0.00
About AMTM AMENTUM HOLDINGS INC
Amentum Holdings Inc is engaged in engineering and technology solutions. The United States and its allies trust it to address their technical and complex scientific, security, and sustainability challenges.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.